Global AI in Clinical Trials Market Overview 2023-2035: AI Integration Offers Hope in Streamlining Drug Development

Dublin, Aug. 18, 2023 (GLOBE NEWSWIRE) -- The "AI in Clinical Trials Market: Software and Service Providers - Distribution by Trial Phase, Target Therapeutic Area, End-user and Key Geographical Regions, 2023-2035" report has been added to ResearchAndMarkets.com's offering.

The global AI in clinical trials market is estimated to be worth $1.4 billion in 2023, with a projected compound annual growth rate (CAGR) of 16% during the forecast period. Clinical trials are an essential part of drug development, but they are known for being time-consuming and costly, with a relatively low success rate. It is estimated that a drug takes around 10 years and over $2.5 billion in capital investment before reaching the market, with clinical trials accounting for nearly 50% of the time and capital expenditure during drug development.

The success rate of drug candidates advancing from clinical trials to obtaining marketing approval has remained relatively constant at approximately 10% - 20% over the past few decades. Various factors contribute to clinical stage intervention failure, such as inadequate study design, incomplete patient recruitment, improper subject stratification, and high rates of clinical trial participant attrition. To overcome these challenges and streamline the clinical trial process, stakeholders in the pharmaceutical industry are turning to innovative solutions and strategies, one of which involves integrating AI in drug development.

AI has the potential to revolutionize traditional methods in clinical trials by helping to integrate and analyze large volumes of data, optimizing future research initiatives, and addressing issues related to trial design, patient recruitment and retention, site selection, data interpretation, and treatment evaluation. The ability of AI to automate and streamline labor-intensive tasks, improve decision-making processes, and identify patterns and trends in complex datasets has garnered significant attention and interest from stakeholders in the pharmaceutical industry.

The rising interest in AI in clinical trials is evidenced by the significant investment in the field. In the first nine months of 2021, more than $20 billion was invested in AI companies focused on healthcare, surpassing the prior year's investment of approximately $15 billion. This influx of investment indicates healthy growth potential for the AI in clinical trials market during the forecast period.

The current market landscape includes around 130 players with expertise in providing various AI software and services to streamline clinical studies. About 80% of these companies focus on leveraging machine learning and deep learning algorithms to minimize data-based errors and access multiple data points simultaneously. Stakeholders have been forming partnerships and collaborations related to AI in clinical trials with other industry/non-industry players to expand their capabilities and build comprehensive product/service portfolios.

Overall, the AI in clinical trials market is poised for significant growth, driven by increasing demand for AI solutions to improve patient recruitment, clinical data analysis, and overall trial efficiency. Oncological disorders are likely to be at the forefront of adopting AI solutions, and biotechnology and pharmaceutical companies are expected to hold the majority share in the AI in clinical trials market.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments. The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market, across different geographies.

One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of AI in clinical trials market, over the forecast period. We have provided informed estimates on the likely evolution of the market for the forecast period, 2023-2035. Additionally, historical trends of the market have also been presented for the time period, 2018-2022.

Further, year-wise projections of the current and forecasted opportunity have been segmented based on relevant parameters, such as trial phase (phase I, phase II and phase III), target therapeutic area (cardiovascular disorders, CNS disorders, infectious diseases, metabolic disorders, oncological disorders and other disorders), end-user (pharmaceutical and biotechnology companies, and other end-users) and key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa). In order to account for future uncertainties associated with some of the key parameters and to add robustness to the model, the analyst has provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market growth.

The opinions and insights presented in the report were influenced by discussions held with stakeholders in this industry.

The report also features detailed transcripts of interviews held with various industry stakeholders:

• Danielle Ralic (Co-Founder, Chief Executive Officer and Chief Technology Officer, Ancora.ai)
• Wout Brusselaers (Founder and Chief Executive Officer, Deep 6 AI)
• Dimitrios Skaltsas (Co-Founder and Executive Director, Intelligencia)
• R. A. Bavasso (Founder and Chief Executive Officer, nQ Medical)
• Grazia Mohren (Head of Marketing), Michael Shipton (Chief Commercial Officer), Darcy Forman (Chief Delivery Officer), Troy Bryenton (Chief Technology Officer, Science 37)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Artificial Intelligence (AI)
3.3. Subfields of AI
3.4. Applications of AI in Healthcare
3.4.1. Drug Discovery
3.4.2. Drug Manufacturing
3.4.3. Marketing
3.4.4. Diagnosis and Treatment
3.4.5. Clinical Trials
3.5. Applications of AI in Clinical Trials
3.6. Challenges Associated with the Adoption of AI
3.7. Future Perspective

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. AI in Clinical Trials: AI Software and Service Providers Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters (Region)
4.2.5. Analysis by Key Offering(s)
4.2.6. Analysis by Business Model(s)
4.2.7. Analysis by Deployment Option(s)
4.2.8. Analysis by Type of AI Technology
4.2.9. Analysis by Application Area(s)
4.2.10. Analysis by Potential End-user(s)

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AiCure
5.3. Antidote Technologies
5.4. Deep 6 AI
5.5. Innoplexus
5.6. IQVIA
5.7. Median Technologies
5.8. Medidata
5.9. Mendel.ai
5.10. Phesi
5.11. Saama Technologies
5.12. Signant Health
5.13. Trials.ai

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. AI in Clinical Trials
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Number of Patients Enrolled
6.3.3. Analysis by Trial Phase
6.3.4. Analysis by Trial Status
6.3.5. Analysis by Trial Registration Year and Status
6.3.6. Analysis by Type of Sponsor
6.3.7. Analysis by Patient Gender
6.3.8. Analysis by Patient Age
6.3.9. Word Cloud Analysis: Emerging Focus Areas
6.3.10. Analysis by Target Therapeutic Area
6.3.11. Analysis by Study Design
6.3.12. Most Active Players: Analysis by Number of Clinical Trials
6.3.13. Analysis of Clinical Trials by Geography
6.3.14. Analysis of Clinical Trials by Geography and Trial Status
6.3.15. Analysis of Patients Enrolled by Geography and Trial Registration Year
6.3.16. Analysis of Patients Enrolled by Geography and Trial Status

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. AI in Clinical Trials: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Application Area
7.3.5. Analysis by Target Therapeutic Area
7.3.6. Analysis by Type of Partner
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Analysis by Geography

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. AI in Clinical Trials: List of Funding and Investments
8.3.1. Analysis by Year of Funding
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Type of Funding and Amount Invested
8.3.5. Most Active Players: Analysis by Amount Raised and Number of Funding Instances
8.3.6. Leading Investors: Analysis by Number of Funding Instances
8.3.7. Analysis of Amount Invested by Geography
8.3.8. Analysis of Number of Funding Instances by Geography
8.4. Concluding Remarks

9. BIG PHARMA INITIATIVES
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Analysis by Year of Initiative
9.4. Analysis by Type of Initiative
9.5. Analysis by Application Area of AI
9.6. Analysis by Target Therapeutic Area
9.7. Benchmarking Analysis: Big Pharma Players

10. AI IN CLINICAL TRIALS: USE CASES
10.1. Chapter Overview
10.2. Use Case 1: Collaboration between Roche and AiCure
10.2.1. Roche
10.2.2. AiCure
10.2.3. Business Needs
10.2.4. Objectives Achieved and Solutions Provided
10.3. Use Case 2: Collaboration between Takeda and AiCure
10.3.1. Takeda
10.3.2. AiCure
10.3.3. Business Needs
10.3.4. Objectives Achieved and Solutions Provided
10.4. Use Case 3: Collaboration between Teva Pharmaceuticals and Intel
10.4.1. Teva Pharmaceuticals
10.4.2. Intel
10.4.3. Business Needs
10.4.4. Objectives Achieved and Solutions Provided
10.5. Use Case 4: Collaboration between Unnamed Pharmaceutical Company and Antidote
10.5.1. Antidote
10.5.2. Business Needs
10.5.3. Objectives Achieved and Solutions Provided
10.6. Use Case 5: Collaboration between Unnamed Pharmaceutical Company and Cognizant
10.6.1. Cognizant
10.6.2. Business Needs
10.6.3. Objectives Achieved and Solutions Offered
10.7. Use Case 6: Collaboration between Cedars-Sinai Medical Center and Deep 6 AI
10.7.1. Cedars-Sinai Medical Center
10.7.2. Deep 6 AI
10.7.3. Business Needs
10.7.4. Objectives Achieved and Solutions Offered
10.8. Use Case 7: Collaboration between GlaxoSmithKline (GSK) and PathAI
10.8.1. PathAI
10.8.2. GlaxoSmithKline (GSK)
10.8.3. Business Needs
10.8.4. Objectives Achieved and Solutions Provided
10.9. Use Case 8: Collaboration between Bristol Myers Squibb (BMS) and Concert AI
10.9.1. Concert AI
10.9.2. Bristol Myers Squibb (BMS)
10.9.3. Business Needs
10.9.4. Objectives Achieved and Solutions Provided

11. VALUE CREATION FRAMEWORK: A STRATEGIC GUIDE TO ADDRESS UNMET NEEDS IN CLINICAL TRIALS
11.1. Chapter Overview
11.2. Unmet Needs in Clinical Trials
11.3. Key Assumptions and Methodology
11.4. Key Tools / Technologies
11.4.1. Blockchain
11.4.2. Big Data Analytics
11.4.3. Real-world Evidence
11.4.4. Digital Twins
11.4.5. Cloud Computing
11.4.6. Internet of Things (IoT)
11.5. Trends in Research Activity
11.6. Trends in Intellectual Capital
11.7. Extent of Innovation versus Associated Risks
11.8. Results and Discussion
11.9. Summary

12. COST SAVING ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Overall Cost Saving Potential of AI in Clinical Trials, 2023-2035
12.3.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035
12.3.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035
12.3.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035
12.3.4. Cost Saving Potential in Patient Recruitment, 2023-2035
12.3.5. Cost Saving Potential in Patient Retention, 2023-2035
12.3.6. Cost Saving Potential in Staffing and Administration, 2023-2035
12.3.7. Cost Saving Potential in Site Monitoring, 2023-2035
12.3.8. Cost Saving Potential in Source Data Verification, 2023-2035
12.3.9. Cost Saving Potential in Other Procedures, 2023-2035

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global AI in Clinical Trials Market, 2023-2035
13.3.1. AI in Clinical Trials Market: Distribution by Trial Phase, 2023 and 2035
13.3.2. AI in Clinical Trials Market: Distribution by Target Therapeutic Area, 2023 and 2035
13.3.3. AI in Clinical Trials Market: Distribution by End-user, 2023 and 2035
13.3.4. AI in Clinical Trials Market: Distribution by Key Geographical Regions, 2023 and 2035

14. CONCLUSION

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Ancora.ai
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Danielle Ralic, Co-Founder, Chief Executive Officer and Chief Technology Officer
15.3. Deep 6 AI
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Wout Brusselaers, Founder and Chief Executive Officer
15.4. Intelligencia
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Dimitrios Skaltsas, Co-Founder and Executive Director
15.5. nQ Medical
15.5.1. Company Snapshot
15.5.2. Interview Transcript: R. A. Bavasso, Founder and Chief Executive Officer
15.6. Science 37
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Grazia Mohren (Head of Marketing), Michael Shipton (Chief Commercial Officer), Darcy Forman (Chief Delivery Officer), Troy Bryenton (Chief Technology Officer)

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

• AbbVie
• Accelmed
• Accenture
• Acclinate
• Actelion Pharmaceuticals
• Adara Ventures
• AG Mednet
• Agent Health
• A.I. VALI
• AiCure
• Aidar Health
• AITIA
• AKESOgen
• AKRN Scientific Consulting (acquired by NAMSAN)
• Alexandria Venture Investments
• Alira Health
• AliveCor
• AllianceBernstein
• Alliance for Clinical Trials in Oncology
• Allucent
• Alpha MD
• ALS Association
• Alter Venture Partners
• Amadeus Capital Partners
• Amber Specialty Pharmacy
• American Society of Clinical Oncology (ASCO)
• Amgen
• Amgen Ventures
• Amplify
• Ancora.ai
• Anthem
• Anthemis Exponential Ventures
• Antidote Technologies
• Aperio
• APEX Digital Health
• APEX Ventures
• Arondor
• Artificial Intelligence in Medicine (AIM) (a subsidiary of Inspirata)
• ArtiQ
• Arvinas
• Asahi Kasei
• Ascension Ventures
• Aspen Insights
• Assistance Publique Hopitaux de Paris
• AstraZeneca
• ATAI Life Sciences
• AV8 Ventures
• Avalanche Venture Capital
• Avident Health
• Avira Digital
• Aviva Ventures
• Avon
• Baird Capital
• Baron Davis Enterprises
• Beacon Biosignals
• BEPATIENT
• Beyond Celiac
• Big Pi Ventures
• Bioforum
• Biofourmis
• Bioinfogate (acquired by Clarivate)
• Biomatics Capital
• Biomedical Advanced Research and Development Authority (BARDA)
• Blue Heron Capital
• Boehringer Ingelheim
• Boehringer Ingelheim Venture Fund (BIVF)
• Bold Capital Partners
• Bolton NHS Foundation Trust
• BootstrapLabs
• Boreal Ventures
• Bpifrance
• Brainomix
• Brainpan Innvovations
• Bridge Biotherapeutics
• Bristol Myers Squibb (BMS)
• Brite Health
• Bronze Valley
• BUDDI.AI
• BullFrog AI
• Cambridge Cognition
• Canary Speech
• Carebox
• Carenity (acquired by EvidentIQ)
• Carle Health
• Carlyle
• Casdin Capital
• Cathay Innovation
• Cavendish Impact Foundation (CIF)
• Cedar Health Research
• Celgene
• CellCarta
• Central Ohio Primary Care Physicians (COPC)
• The Centre for Aging + Brain Health Innovation (CABHI )
• Cerba Research
• Chainlink
• Charterhouse Capital Partners
• Chartline Capital Partners
• ChemAxon
• Children's Oncology Group (COG)
• Chimera Partners
• Cigna Ventures
• CIMS Global
• Citeline ( a subsidiary of Norstella)
• Clario
• Clarivate
• ClearPoint Investment Partners
• Clinerion
• Clinevo Technologies
• clinicalAI
• CliniOps
• Clinithink
• ClinScape
• ClinTex
• CMIC Group
• Cognizant
• Community Health Network
• ConcertAI
• Constant Companion
• Creadev
• Crestle.ai (acquired by Doc.ai)
• Crista Galli Ventures
• Cumulus Neuroscience
• Curenetics
• Curify.ai
• CVS Health
• Dassault Systemes
• DataON
• Datavant
• DCM Ventures
• DCVC Bio
• Debiopharm
• Decibel Therapeutics
• Declaration Partners
• Deep 6 AI
• Deep Lens (acquired by Paradigm)
• DeepTrial
• Defense Health Agency
• Dementia Discovery Fund (DDF)
• Department of Veteran Affairs
• Deutsche Investitions und Entwicklungsgesellschaft (DEG)
• DiA Imaging Analysis
• doc.ai (acquired by Sharecare)
• Dong-A Socio Holdings
• EBSCO Information Services
• Echo Health Ventures
• EDBI
• Edison Partners
• Eight Roads Ventures
• eimageglobal
• EIT Health
• Elliott Investment Management
• Entrepreneur First
• Epilepsy Study Consortium
• Ergomed
• Erlanger Health System
• ERYTECH
• Espresso Capital
• Eugene M. Lang Foundation
• European Commission
• European Investment Bank
• European Regional Development Fund (ERDF)
• Excelra
• Experimental Cancer Medicine Centre (ECMC)
• Experimind
• Faber
• fathom it group
• FinLab EOS VC Fund
• First Analysis Corporation
• First Trust Capital Partners
• Florida Cancer Affiliates
• Folklore Ventures
• Fosun RZ Capital
• GE Healthcare
• Genentech
• General Atlantic
• General Catalyst
• Genoa Ventures
• Genomenon
• Genpro Research
• GlaxoSmithKline (GSK)
• Global Alzheimer's Platform Foundation
• Gloucestershire Cancer Alliance (SWAG)
• Google
• GV (formerly Google Ventures)
• Greater Gift
• Grey Sky Venture Partners
• Grove Ventures
• GSR Ventures
• Guy's and St Thomas' NHS Foundation Trust
• H1
• H2O.ai
• Halo Health
• Hambro Perks
• Healint
• Healthix
• HealthMatch
• HealthVerity
• Hematology-Oncology Associates of Central New York (HOA)
• Jiangsu Hengrui Pharmaceuticals
• Herefordshire and Worcestershire Health and Care NHS Trust
• Heritage Medical Group
• Highline Sciences
• HCLTech
• Horizon Therapeutics
• Human API
• IBM
• iClusion
• ICON
• IKJ Capital
• iLoF
• IMA Group
• IMNA Solutions
• ImpactAssets
• Inato
• Indegene
• iNDX.Ai
• Inflection Biosciences
• Innoplexus
• Innovaderm
• Innovatrix Capital
• Insight Partners
• Insilico Medicine
• Inspirata
• Inspire
• Intel
• Intel Capital (a subsidiary of Intel)
• Intelligencia.ai
• Intermountain Ventures
• Investissement Quebec
• Iowa First Capital Fund
• Iowa Innovation Acceleration Fund
• IQ Capital
• IQVIA
• IXICO
• Janssen Pharmaceuticals
• Jianke
• Johns Hopkins University
• Johnson & Johnson
• Karyopharm Therapeutics
• Keosys
• Khosla Ventures
• King's Health Partners
• Kinship
• Kleiner Perkins
• Kognitic
• Labcorp
• Lambda Therapeutic Research
• LaunchCapital
• Launch Therapeutics
• LBO France
• Leal Health
• Legit.Health
• LEO Pharma
• Leukemia & Lymphoma Society
• Lieber Institute for Brain Development
• Life Image (acquired by Intelerad Medical SystemsT )
• LifeArc
• Lightship
• Linguamatics (a subsidiary of IQVIA)
• Liquid 2 Ventures
• LMK Clinical Research Consulting
• Lokavant (a subsidiary of Roivant Sciences)
• LSU Health New Orleans
• Lunar Ventures
• M12 (formerly known as Microsoft Ventures)
• Massachusetts General Hospital
• Massive Bio
• MassMutual Ventures
• Matrix Capital Management
• Matrix Partners
• Maverick Ventures
• Maxer Consulting
• Mayfield Fund
• Mayo Clinic
• Mayo Clinic Ventures (a subsidiary of Mayo Clinic)
• McKesson Ventures (a subsidiary of McKesson)
• Medable
• Median Technologies
• Medica
• Medical Research Network (MRN)
• Medidata Solutions
• mediri
• Medpace
• MEDSOFT
• Medtronic
• Memorial Sloan Kettering Cancer Center (MSK)
• Mendel.ai
• Menlo Ventures
• Merck
• Merck Global Health Innovation Fund (Merck GHI) (a subsidiary of Merck)
• Microsoft
• Millennium Technology Value Partners
• Mitsui
• Moderna
• MSD Global Health Innovation Fund (MGHIF)
• MTIP
• Mubadala Capital
• Nanox
• National Cancer Institute (NCI)
• National Institute of Allergy and Infectious Diseases (NIAID)
• National Institute of Mental Health (NIMH)
• National Minority Health Association (NMHA)
• NEC
• NEC OncoImmunity (a subsidiary of NEC)
• NeoGenomics
• NetraMark
• NeuroEndocrine Cancer Australia
• New Enterprise Associates
• New Leaf Venture Partners
• Nex Cubed
• Next Level Ventures
• nference
• NJF Capital
• Nor-Tech
• North American Science Associates (NAMSA)
• Northpond Ventures
• Nova Discovery
• Novartis
• Novoic
• Novotech
• nQ Medical
• Nucleai
• NuvoAir
• Oak HC/FT
• Obvious Ventures
• Ocala Oncology
• Octopus Ventures
• Olive Tree
• OMRON Healthcare
• OncoBay Clinical
• OncoSec Medical
• One Nucleus
• OneStudyTeam
• Openspace Ventures
• Opyl
• Oracle
• Otium Venture
• ?URA Health
• Overline Venture Capital
• Owkin
• Oxford Finance
• University of Oxford Innovation Fund (UOIF)
• P1vital
• P360
• P3Life
• Paige AI
• Palisades Growth Capital
• Pancare Foundation
• Pangaea Data
• Paradigm
• Parexel
• Parkwalk Advisors
• Partech
• Passage AI
• Patchai (acquired by Alira Health)
• PathAI
• Patient iP
• PatientPoint
• PatienTrials
• Patiro
• Pear Therapeutics
• Pepgra
• Perceiv AI
• Perceptive Advisors
• Perthera.ai
• Pfizer
• Pfizer Ventures (a subsidiary of Pfizer)
• Pharmamodelling
• Phastar
• phaware
• Phesi
• physIQ
• Plug and Play Ventures
• Point72 Ventures
• Population Health Partners
• PPC (merged with Novotech)
• PRA Health Sciences
• Precipio
• Prime Capital
• Pritzker Group
• ProofPilot
• Propeller Health
• Protocols.io
• PWNHealth
• Qmetrics Technologies
• Qualcomm Ventures
• Quality Cancer Care Alliance Network (QCCA)
• Quibim
• Quiet Capital
• Qure.ai
• Qwince
• Radical Ventures
• RadMD (acquired by Medica Group)
• Raylytic
• re.Mind Capital
• RealTime Software Solutions
• Red Abbey Labs
• Reify Health
• Remarque Systems
• Renmin Hospital of Wuhan University
• Rev1 Ventures
• Revo Capital
• Revolution Growth
• Risklick
• Rittenhouse Ventures
• Roche
• Roivant Sciences
• Royal Philips
• Rural Vitality Fund
• Rymedi
• Saama Technologies
• San Raffaele Hospital
• Sanofi
• Sanofi Ventures (a subsidiary of Sanofi)
• Scale Ventures
• Science37
• Scipher Medicine
• Self-Care Catalysts
• Semicrol
• sensedat
• Sensyne Health
• Sequoia India
• Serena and Fly Ventures
• ServiceNow
• Servier
• SGInnovate
• Shandong University
• Sierra Ventures
• Sigmasoft
• Signant Health
• Silicon Valley Bank (SVB)
• SimBioSys
• Singtel Innov8
• SiteGround Capital
• SiteRx
• Sixth Street
• Small Business Innovation Research (SBIR)
• Smedvig Capital
• SoftBank Vision Fund
• Somerset
• Sopris Capital
• SOSV
• Sourcia
• Southern Oncology Specialists
• Sozo Ventures
• SpringRock Ventures
• Square Peg
• Square Peg Capital
• Stanford Angels
• Stratus
• SubjectWell
• Sway Ventures
• SyMetric
• Symphony Clinical Research (acquired by ICON)
• SymphonyAI
• Syneos Health
• Synetro
• Synexus
• System Applications and Products in Data Processing (SAP)
• T. Rowe Price
• Taliaz
• Talkdesk
• Tamarind Hill Fund
• Teal Ventures
• Tech Transfer UPV
• TEDCO's Seed Fund
• Tempus
• Tencent Holdings
• Tenthpin
• TeraRecon
• TFS Services
• The Angels' Forum
• ThoughtSphere
• THREAD
• Tiger Global Management
• Timberline Holding
• TissueTech
• Translational Drug Development (TD2)
• TransPerfect Life Sciences
• Trialbee
• Trials.ai (acquired by ZS Associates)
• TrialSense
• Tribeca Venture Partners
• TriNetX
• TT Capital Partners
• TTi Health Research & Economics
• U.S. Food and Drug Administration (FDA)
• U.S. Veteran's Affairs
• UCB Biopharma
• UK Future Fund
• Underscore Venture Capital
• UnityPoint Health Ventures
• University of California
• University of Pennsylvania
• University of Pittsburgh
• Unlearn.AI
• Vastrax
• VeriSIM
• VersaTrial
• Vertex Ventures
• Veterans Prostate Cancer Awareness (VPCa)
• VIDA
• Viroclinics-DDL (acquired by Cerba HealthCare)
• VirTrial
• Vivoryon Therapeutics
• Viz.ai
• WallachBeth Capital
• WCG Clinical
• Wefight
• Wiley
• Winterlight Labs
• Wittington Ventures
• Worldwide Clinical Trials
• WP Global Partners
• XpertPatient
• Zola Global Investors
• ZS Associates

For more information about this report visit https://www.researchandmarkets.com/r/uq67eu

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• AI in Clinical Trials Market